FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2561567034> ?p ?o ?g. }

• W2561567034 abstract "Introduction: SGI-110 is a dinucleotide of decitabine and deoxyguanosine and a novel subcutaneous (SQ) hypomethylating agent. In a previous Phase 1 (dose escalation) study, we found in relapsed/refractory (r/r) AML patients who were treated with SGI-110 (36 mg/m2-125 mg/m2) subcutaneously (SQ) daily for 5 days a correlation between low LINE-1 demethylation induction, a three gene expression classifier score (low CDA, low P15 and high DNMT3B) and resistance to SGI-110. Here, we analyzed r/r AML patients (n = 122) from Phase 1/2 studies treated at pharmacologically effective doses of SGI-110 looking for determinants of hypomethylation and response. Methods: Phase 1 patients with r/r AML (n = 27) who were treated at a therapeutic dose range of SGI-110 (35 mg/m2 - 125 mg/m2) by SQ daily for 5 days. Phase 2 study r/r AML patients received 60 mg/m2 SQ daily for 5 days (n = 22), 90 mg/m2 SQ daily for 5 days (n = 25) and 60 mg/m2 SQ daily for 10 days (n = 48). Global DNA methylation at pre/post treatment was estimated by bisulfite-pyrosequencing for the LINE-1 repetitive sequence. We also examined expression of a panel of genes (CDA, P15, P21, DNMT3B, DNMT3A, DNMT1, and CTCF) at baseline by quantitative RT-PCR. Results: We analyzed samples from 122 patients with r/r AML. Median age was 59.6 (range, 23-86), 75 were males (61.5%). Overall, peak LINE-1 demethylation generally occurred on day 8 after daily x 5 treatment, or on day 8 or 15 after daily x 10 treatment. In individual patients, peak LINE-1 demethylation ranged from +4.9% to -56.3%. In 122 r/r AML patients, 28 showed overall remission (23.0%, 15 CR and 13 CRi/CRp). Unsupervised clustering by expression of a panel of genes at baseline grouped the patients into two clusters: A (N = 95, response rate = 29.5%) and B (N = 27, response rate = 0%). Cluster B is characterized by high DNMT3b expression, low P15 expression, low CDA expression (average Z-score 1.44 ± 0.26 in cluster B compared to -1.26 ± 0.14 in clusters A, p Conclusions: In a phase 1/2 study of SGI-110, we identified in r/r AML patients a gene expression signature (high DNMT3B, low P15, and low CDA) associated with reduced demethylation and resistance to SGI-110 and we found strong trends for associations between demethylation and response. Citation Format: Woonbok Chung, Pietro Taverna, John Lyons, Yong Hao, Mohammad Azab, Hagop Kantarjian, Patricia Kropf, Jean-Pierre Issa. Determinants of hypomethylation and clinical responses in relapsed/refractory AML patients treated with SGI-110, a novel hypomethylating agent in a phase 1/2 study. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2952. doi:10.1158/1538-7445.AM2015-2952" @default.
• W2561567034 created "2017-01-06" @default.
• W2561567034 creator A5018689852 @default.
• W2561567034 creator A5019816977 @default.
• W2561567034 creator A5023473953 @default.
• W2561567034 creator A5033584583 @default.
• W2561567034 creator A5050224107 @default.
• W2561567034 creator A5064201088 @default.
• W2561567034 creator A5079853830 @default.
• W2561567034 creator A5090435894 @default.
• W2561567034 date "2015-08-01" @default.
• W2561567034 modified "2023-09-26" @default.
• W2561567034 title "Abstract 2952: Determinants of hypomethylation and clinical responses in relapsed/refractory AML patients treated with SGI-110, a novel hypomethylating agent in a phase 1/2 study" @default.
• W2561567034 doi "https://doi.org/10.1158/1538-7445.am2015-2952" @default.
• W2561567034 hasPublicationYear "2015" @default.
• W2561567034 type Work @default.
• W2561567034 sameAs 2561567034 @default.
• W2561567034 citedByCount "0" @default.
• W2561567034 crossrefType "proceedings-article" @default.
• W2561567034 hasAuthorship W2561567034A5018689852 @default.
• W2561567034 hasAuthorship W2561567034A5019816977 @default.
• W2561567034 hasAuthorship W2561567034A5023473953 @default.
• W2561567034 hasAuthorship W2561567034A5033584583 @default.
• W2561567034 hasAuthorship W2561567034A5050224107 @default.
• W2561567034 hasAuthorship W2561567034A5064201088 @default.
• W2561567034 hasAuthorship W2561567034A5079853830 @default.
• W2561567034 hasAuthorship W2561567034A5090435894 @default.
• W2561567034 hasConcept C104317684 @default.
• W2561567034 hasConcept C126322002 @default.
• W2561567034 hasConcept C142424586 @default.
• W2561567034 hasConcept C143998085 @default.
• W2561567034 hasConcept C150194340 @default.
• W2561567034 hasConcept C185592680 @default.
• W2561567034 hasConcept C190727270 @default.
• W2561567034 hasConcept C2776012956 @default.
• W2561567034 hasConcept C2776239401 @default.
• W2561567034 hasConcept C2777063308 @default.
• W2561567034 hasConcept C2780235182 @default.
• W2561567034 hasConcept C29730261 @default.
• W2561567034 hasConcept C31760486 @default.
• W2561567034 hasConcept C55493867 @default.
• W2561567034 hasConcept C71924100 @default.
• W2561567034 hasConcept C86803240 @default.
• W2561567034 hasConcept C87355193 @default.
• W2561567034 hasConcept C90924648 @default.
• W2561567034 hasConcept C98274493 @default.
• W2561567034 hasConceptScore W2561567034C104317684 @default.
• W2561567034 hasConceptScore W2561567034C126322002 @default.
• W2561567034 hasConceptScore W2561567034C142424586 @default.
• W2561567034 hasConceptScore W2561567034C143998085 @default.
• W2561567034 hasConceptScore W2561567034C150194340 @default.
• W2561567034 hasConceptScore W2561567034C185592680 @default.
• W2561567034 hasConceptScore W2561567034C190727270 @default.
• W2561567034 hasConceptScore W2561567034C2776012956 @default.
• W2561567034 hasConceptScore W2561567034C2776239401 @default.
• W2561567034 hasConceptScore W2561567034C2777063308 @default.
• W2561567034 hasConceptScore W2561567034C2780235182 @default.
• W2561567034 hasConceptScore W2561567034C29730261 @default.
• W2561567034 hasConceptScore W2561567034C31760486 @default.
• W2561567034 hasConceptScore W2561567034C55493867 @default.
• W2561567034 hasConceptScore W2561567034C71924100 @default.
• W2561567034 hasConceptScore W2561567034C86803240 @default.
• W2561567034 hasConceptScore W2561567034C87355193 @default.
• W2561567034 hasConceptScore W2561567034C90924648 @default.
• W2561567034 hasConceptScore W2561567034C98274493 @default.
• W2561567034 hasLocation W25615670341 @default.
• W2561567034 hasOpenAccess W2561567034 @default.
• W2561567034 hasPrimaryLocation W25615670341 @default.
• W2561567034 hasRelatedWork W126098488 @default.
• W2561567034 hasRelatedWork W2405418665 @default.
• W2561567034 hasRelatedWork W2414304097 @default.
• W2561567034 hasRelatedWork W2434901231 @default.
• W2561567034 hasRelatedWork W2504451653 @default.
• W2561567034 hasRelatedWork W2529404918 @default.
• W2561567034 hasRelatedWork W2529888484 @default.
• W2561567034 hasRelatedWork W2532183409 @default.
• W2561567034 hasRelatedWork W2555832724 @default.
• W2561567034 hasRelatedWork W2556574691 @default.
• W2561567034 hasRelatedWork W2564350924 @default.
• W2561567034 hasRelatedWork W2579153536 @default.
• W2561567034 hasRelatedWork W2581054618 @default.
• W2561567034 hasRelatedWork W2584347108 @default.
• W2561567034 hasRelatedWork W2593543199 @default.
• W2561567034 hasRelatedWork W2599450528 @default.
• W2561567034 hasRelatedWork W2896328719 @default.
• W2561567034 hasRelatedWork W2963483321 @default.
• W2561567034 hasRelatedWork W2999085205 @default.
• W2561567034 hasRelatedWork W3136777595 @default.
• W2561567034 isParatext "false" @default.
• W2561567034 isRetracted "false" @default.
• W2561567034 magId "2561567034" @default.
• W2561567034 workType "article" @default.